The authors present a fluorescence lifetime-based kinase binding assay that identifies and characterizes compounds that bind to the adenosine triphosphate (ATP)-binding pocket of a range of tyrosine and serine/threonine kinases. The assay is based on displacement of an Alexa Fluor ® 647 conjugate of staurosporine from the ATP-binding site of a kinase, which is detected by a change in the fluorescence lifetime of the probe between the free (displaced) and kinase-bound states. The authors screened 257 kinases for specific binding and displacement of the Alexa Fluor ® 647-staurosporine probe and found that approximately half of the kinases tested could potentially be assayed with this method. They present inhibitor binding data against 4 selected serine/threonine kinases and 4 selected tyrosine kinases, using 6 commonly used kinase inhibitors. Two of these kinases were chosen for further studies, in which inhibitor binding data were compared to inhibition of kinase activity using 2 separate activity assay formats. Rank-order potencies of compounds were similar, but not identical, between the binding and activity assays. It was postulated that these differences could be caused by the fact that the assays are measuring distinct phenomena, namely, activity versus binding, and in a purified recombinant kinase preparation, there can exist a mixture of active and nonactivated kinases. To explore this possibility, the authors compared binding affinity for the probe using 2 kinases in their respective nonactivated and activated (phosphorylated) forms and found a kinase-dependent difference between the 2 forms. This assay format therefore represents a simple method for the identification and characterization of small-molecule kinase inhibitors that may be useful in screening a wide range of kinases and may be useful in identifying small molecules that bind to kinases in their active or nonactivated states. (Journal of Biomolecular Screening 2007:828-841) 
INTRODUCTION
B ECAUSE KINASES ARE AN IMPORTANT CLASS of targets in the druggable genome, a plethora of fluorescence-based assay formats have been described and are in routine use for the identification and characterization of small-molecule kinase inhibitors. [1] [2] [3] [4] [5] [6] [7] Although each assay format has its proponents, the reality is that all assay formats contain trade-offs in terms of sensitivity, ease of use, applicability to different kinase targets, resistance to interference, and relevance to in vivo biology. The particular kinase assay strategy employed must weigh these factors against the objectives of the assay. In terms of simplicity of assay design, an assay that directly measures the ability of a small molecule to bind to the active site of a kinase (in the absence of kinase activity) offers advantages over an assay that indirectly measures this ability by monitoring kinase activity in the presence of such a compound. At a minimum and by definition, substrate is not required, nor is there a requirement for detection of product formation or substrate depletion.
Several nonactivity-based kinase binding assays have been described in the literature, both fluorescence based and nonfluorescence based. For example, a competitive scintillation proximity assay using a radiolabeled, nonhydrolyzable adenosine triphosphate (ATP) analog, AMP-PCP, has been used to characterize inhibitors of glycogen synthase kinase β. 8 Mass spectrometrybased assays that detect the retardation of compounds flowing through capillaries containing immobilized kinase have been described, 9 as have other mass spectrometry-based methods in which mixtures of compounds are mixed with a kinase target, unbound compounds are separated by size-exclusion chromatography, and compounds that bind to the target are identified by their characteristic mass after dissociation from the kinase. 10 Competition of ATP from nanowire-immobilized kinase has been detected by a change in conductance of the nanowire. 11 The ability of a compound to displace a phage-displayed kinase from a surface containing immobilized inhibitor has been described using a readout of either traditional phage plaque assays or quantitative PCR of phage DNA. 12 A coupled, enzyme fragment complementation assay has been described in which a small fragment of β-galactosidase was coupled to staurosporine, which was then bound to a target kinase. Displacement of the staurosporine-βgalactosidase fragment allowed association with a larger fragment of β-galactosidase and formation of active β-galactosidase, which could be measured with a chemiluminescent substrate. 13 In comparison, fewer fluorescence-based kinase binding assays have been described. An intrinsically fluorogenic mitogenactivated protein (MAP) kinase inhibitor, SK&F 86002, has been used to characterize inhibitors of p38 MAP kinases. 14 Another binding assay for p38α (MAPK14) has been described, in which the small-molecule inhibitor M38 was coupled to Alexa Fluor ® (AF647) 647 and used as a probe against biotinylated p38α. 15 Upon addition of europium-conjugated streptavidin, M38-AF647 that was bound to the kinase could be detected by time-resolved fluorescence (Förster) resonance energy transfer (TR-FRET) between europium and AF647, and displacement of the probe was detected by a decrease in FRET signal. Because the probes used in both of these examples are specific for a narrow range of kinases, these methods would be expected to be limited in terms of the breadth of kinases toward which they could be applied. Very recently, Kashem and colleagues described a fluorescence polarization-based assay using an Oregon Green ® conjugate of a 2,4-diamino-5-nitropyrimidine derivative that binds to the ATPbinding site of the tyrosine kinase ITK. 16 In this assay, compounds that bind to the kinase cause a change in the polarization signal of the fluorescent conjugate, which decreases as the probe gains rotational freedom when it is displaced from the larger kinase.
Because all kinases must contain a binding site for ATP and because many successful kinase-directed drugs bind to the ATP-binding site of the target kinase, we designed a probe directed toward the ATP-binding site based on the broad-spectrum smallmolecule kinase inhibitor staurosporine. Staurosporine is a streptomyces metabolite that has been shown to inhibit a wide range of tyrosine and serine/threonine kinases through interaction with the ATP-binding site of the kinase. The crystal structure of staurosporine bound to a number of kinases has been reported 17 and suggests that modification of the 4′ nitrogen of staurosporine should minimally affect the ability of the molecule to bind to the ATP-binding site. In addition, others have previously shown that modification of this nitrogen results in a compound that maintains its ability to bind to a range of kinases. 12, 13 Because we 18 and others [19] [20] [21] have previously shown that fluorophores conjugated to small-molecule ligands for protein targets can undergo substantial changes in fluorescence lifetime between the free and bound state, we reasoned that by coupling a fluorescent molecule to staurosporine at this position, we could prepare a fluorescence lifetime-based probe that could be used to identify and characterize ATP-competitive inhibitors for a wide range of kinases.
Direct measurement of fluorescence lifetime has emerged as a powerful technique for cellular imaging (known as fluorescence lifetime imaging microscopy) 22 but has not been routinely applied to high-throughput screening (HTS) applications. Fluorescence lifetime refers to the average time that a fluorescent molecule spends in the excited state before releasing the energy that it has absorbed as a photon. The radiative de-excitation pathway that results in the emission of a photon is in competition with nonradiative de-excitation processes that are often collectively referred to as "environmental effects." Thus, if the environment of a fluorophore changes, its fluorescence lifetime can change as well. Because fluorescence lifetime is an intrinsic property, it is not sensitive to optical effects that result in a decrease in fluorescence intensity, such as the presence of colored compounds that absorb excitation or emission radiation (within the limits of the fluorophore signal's being suitably resolvable from background or instrumental noise).
MATERIALS AND METHODS
Purified recombinant kinases and activity assay reagents were from Invitrogen Corporation (Carlsbad, CA). General chemicals and small-molecule inhibitors were from Sigma-Aldrich (St. Louis, MO) or Calbiochem/EMD Biosciences (San Diego, CA). Alexa Fluor ® 647-staurosporine (AF647-staurosporine) was from Molecular Probes (Eugene, OR).
Fluorescence lifetime and time-resolved fluorescence measurements
Fluorescence lifetime measurements were performed using a Tecan Ultra Evolution plate reader (Tecan, Durham, NC) equipped for time-correlated single-photon counting (TCSCP) to determine fluorescence lifetime. Sample wells were excited using the 635-nm laser at a 40-MHz repetition rate, with a data acquisition time of 1 s per well. Emission was measured at 680 nm. Data were fitted to a single exponential decay model, and the data collection offset over which the decay curve was fit was fixed to a constant value for all wells. Previous experience with fluorescence lifetime-based assays suggested that more robust binding data could be obtained using these software settings and forcing a fit to a single exponential decay model, despite the fact that the decay curves are often multiexponential. 18 TR-FRET measurements of kinase activity were performed on a BMG PheraStar plate reader using the LanthaScreen™ filter module. TR-FRET values were taken as the ratio of raw acceptor to donor intensities measured over a 200-µs signal integration time following a 100-µs postexcitation delay. Kinase inhibition assays in the FRET-based Z′-LYTE™ format 5 were performed by Invitrogen's SelectScreen™ profiling service (Paisley, Scotland). All fluorescence assays and measurements were performed in black Corning low-volume 384-well plates (Corning #3676, Corning, NY).
Screening for kinases that bind specifically to AF647-staurosporine
Two hundred fifty-seven purified, recombinant protein kinases were initially arrayed at 0.1 mg/mL in a storage buffer consisting of 50 mM Tris, pH 7.5, 150 mM NaCl, 0.02% Triton X-100, 0.5 mM EDTA, 2 mM DTT, and 50% glycerol in 96well polypropylene plates. The kinases were then diluted into assay plates to a final concentration of 10 µg/mL, in buffer consisting of 20 mM Tris, pH 7.4, and 0.01% NP-40. Each kinase was tested in single wells containing 1 nM AF647-staurosporine in the presence or absence of 1-µM unlabeled staurosporine in a final reaction volume of 20 µL. The concentration of kinase in each well ranged from approximately 100 nM to 200 nM, based on a typical molecular weight of 50 to 100 kD for each kinase. Assay plates were briefly shaken on a microplate shaker and then allowed to incubate 90 min at room temperature prior to measurement of fluorescence lifetime.
Binding and competition assays with select kinases
To determine affinity of the AF647-staurosporine probe for individual kinases, kinases were serially diluted in assay plates in assay buffer consisting of 20 mM Tris, pH 7.4, and 0.01% NP-40. To 10 µL of each kinase concentration, 5 µL of 4% DMSO and 5 µL of 4 nM AF647-staurosporine were added for a final assay volume of 20 µL. For IC 50 determinations of kinase inhibitors, the final concentration of each kinase used was approximately the EC 80 value determined in the binding assay (i.e., the concentration of kinase required to elicit an 80% change in fluorescence lifetime between free and bound probe: MARK2: 7 nM , MARK4: 30 nM, PKC theta: 71 nM, GSK3A: 50 nM, PDGFRβ: 50 nM, Syk: 14 nM, JAK3: 3.5 nM, KDR: 20 nM). Serial dilutions of inhibitors were prepared at 100× in DMSO, diluted further in assay buffer, and 5 µL aliquots were then added to 10-µL solutions of kinase in assay buffer. Compounds were incubated with the kinase for 10 min prior to the addition of 5 µL of 4 nM AF647-staurosporine. All measurements were performed in triplicate, and the data reported represent the average of those measurements. EC 50 and IC 50 data represent the results of a single experiment. Binding and displacement curves were fitted to a variable-slope sigmoidal dose-response curve using GraphPad Prism software (GraphPad Software, San Diego, CA). Z′ determinations using MARK2 were performed using 24 replicate wells containing 0, 2, 4, 6, or 10 nM MARK2 and comparing data between samples containing kinase and the samples lacking kinase.
Inhibition of kinase activity assays
Small-molecule inhibition of kinase activity was analyzed using both a peptide-based TR-FRET assay that detects the association of a fluorescently labeled phosphopeptide (product of the kinase reaction) with a terbium-labeled phosphospecific antibody 23 and a peptide-based FRET assay that uses peptide substrates that are terminally labeled with a coumarin/fluorescein FRET pair and that detects product formation due to differential sensitivity of phosphorylated and nonphosphorylated peptides to proteolytic cleavage. 5 For the TR-FRET assays, 2fold dilutions of KDR or PRKCQ (PKC theta) were first incubated with 400 nM fluorescein-labeled substrates and 20 or 2.5 µM ATP (respective K m,app ) in a total volume of 15 µL in 50 mM Hepes, pH 7.5, 0.01% BRIJ-35, 10 mM MgCl 2 , and 1 mM EGTA. After incubation at room temperature for 1 h, EDTA and Tb-labeled antibody were added to final concentrations of 10 mM and 2 nM, respectively, in a final volume of 20 µL. After a 1-h incubation at room temperature, the plates were read, and data were analyzed as described. In experiments to determine the IC 50 values of inhibitors, the kinase concentration used was the EC 80 concentration of kinase as determined above (PKC theta: 0.25 nM; KDR: 20 nM), and reactions were performed against a serial dilution of inhibitor, with a final concentration of 1% DMSO present in all assay wells. In each assay, the Tb-labeled antibody binds its respective phosphopeptide target with a low-to sub-nM K d , ensuring that even when the antibody is 80% saturated, the underlying kinase assay has proceeded to less than 10% conversion of the peptide substrate. The FRET-based activity assays were performed essentially as described previously 5 by Invitrogen's SelectScreen™ kinase profiling service. Inhibitors were first serially diluted in DMSO at 100× the final assay concentration and then further diluted to a 4× working concentration in 50 mM Hepes, pH 7.5, 0.01% BRIJ-35, 10 mM MgCl 2 , and 1 mM EGTA. A 2× KDR/Tyr 01 peptide mixture was prepared in the same buffer. A total of 2.5 µL of inhibitor solution, followed by 5 µL of kinase/peptide solution, was added to the assay well, and the reaction was started by the addition of 2.5 µL of 4× ATP for a final concentration of 75 µM ATP (K m,app. ) and 2 µM peptide substrate in a 10 µL final volume. PRKCQ (PKC theta) was assayed similarly against its optimized peptide substrate (Ser/Thr 07) and an ATP concentration of 100 µM (K m,app. ). The concentration of kinase (KDR < 20 nM, PKC theta < 450 pM) was such that in the absence of inhibitor, the reaction proceeds to approximately 30% conversion of the peptide substrate. Kinase reactions were allowed to proceed for 60 min at room temperature prior to the addition of a 5-µL solution of development reagent that specifically cleaves nonphosphorylated peptide. Plates were incubated an additional 60 min and then read on a Tecan Safire instrument. Data from the FRET-based activity assay were analyzed using XLfit4 from IDBS (Guildford, UK).
All measurements were performed in triplicate, and the data reported represent the average of those measurements. IC 50 data represent the results of a single experiment.
RESULTS AND DISCUSSION

Development of a fluorescence lifetime-based probe to measure kinase binding by small molecules
Fluorescence lifetime refers to the average time that a fluorescent molecule spends in the excited state between the absorption and emission of a photon. Fluorescence lifetime and the process of fluorescence can be described using a simplified Jablonski diagram, as shown in Figure 1 . When light of a certain range of wavelengths is absorbed by a fluorophore, an electron is promoted from the ground state of the fluorophore (S 0 ) to the 1st excited state (S 1 ), a process that takes place on the femtosecond time scale. Following excitation, there can be a loss in the energy of the system due to conformational changes in the fluorophor, or due to reorientation of solvent molecules around the fluorophore. This relaxation lowers the energy of the excited-state molecule and is responsible for the fact that fluorescence emission occurs at wavelengths longer than the wavelengths of light that will excite the fluorophore. It is from this "relaxed" excited state that fluorescence emission can occur, as the electron moves back from the S 1 to S 0 state. However, the rate (k r ) of the release of this energy as a photon (radiative decay, or fluorescence emission) can be in competition with a variety of other nonradiative relaxation processes that do not result in photonic emission. These processes include phenomena such as resonance energy transfer or other factors that are often collectively referred to as "environmental effects" and that serve to decrease the average amount of time the fluorophore spends in the excited state. These nonradiative processes can differ substantially for a given fluorophore when present in different environments, such as when attached to a ligand that is either free in solution or bound to a receptor. The fluorescence lifetime, τ, is given by the equation
from which it is clear that as the rates of nonradiative relaxation processes increase, the lifetime of the fluorophore decreases. It also follows that as the rate of nonradiative relaxation increases, fewer photons are emitted from the fluorophore, and the intensity of the sample decreases. TCSPC is a technique that can determine fluorescence lifetimes with a high degree of precision. In a TCSPC measurement, a sample is pulsed with excitation light from a laser, and the time between the excitation pulse and the time that a photon is detected from the sample is measured. To ensure true single-photon counting, the excitation intensity is typically set such that 1 photon will be detected for every 100 excitation pulses. If the sample is pulsed every 25 ns (4 × 10 7 pulses/s), such as in the experiments performed here, and if a photon is detected, on average, once every 100 pulses, then a histogram can be constructed from 400,000 data points generated within a 1-s measurement window. This histogram, plotted as photon counts (or intensity) versus time, represents the fluorescence decay of the sample. When multiple nonradiative decay processes are competing with radiative emission of a photon, the decay curve is polyexponential and can be fitted to the equation
where α i is the fractional contribution of each lifetime component i (τ i ) and c is a constant related to background instrument noise. As discussed below, accurate fitting of polyexponential decays in a high-throughput assay can be difficult from a practical standpoint, and the data from a high-throughput fluorescence lifetime-based assay can instead be forced to fit a single exponential model, in which the decay data are fitted to the equation
When the data are fitted to a single exponential decay, the fluorescence lifetime is equal to the negative inverse of the slope of the decay curve when photon counts are plotted on a log scale. This is equivalent to the time it takes for the photon counts (intensity) to decrease by 1/e from the initial intensity.
The Alexa Fluor ® 647-staurosporine conjugate used in these studies was not designed a priori as a lifetime-based binding probe but was in fact synthesized as 1 of a series of probes for an unrelated application. However, it was found during initial experiments that binding of this conjugate to a variety of kinases caused a substantial change in both fluorescence intensity and fluorescence lifetime of the probe itself, and we sought to exploit this property to develop an assay that could characterize small molecules that bound to the ATP-binding site of kinases. The TCSPC decay curves for AF647-staurosporine either free in solution or bound to 100 nM MARK4 are shown in Figure 1 . It is seen that binding of the probe to MARK4 increases the measured lifetime from approximately 1250 ps to approximately 1900 ps and also increases the fluorescence intensity approximately 3-fold. When the emissions are fitted to a single exponential decay model, it is clear from both the curves and the weighted residuals that the decay is polyexponential rather than single exponential. However, we have shown previously 18 that forcing the data fit to a single exponential decay provides robust data suitable for HTS, and that was found to be the case for the assays presented in this study as well. Although it is possible to fit the data to a biexponential decay equation using the software included with the instrument we used, substantially higher numbers of photon counts are required to accurately deconvolute such decays. 24 For example, in a recent study, Moger and colleagues showed that approximately 100 times more photons counts (which would require a 100-fold increase in read time per well) were required to accurately fit data from a 3-component decay mixture relative to that of a 2component decay mixture while maintaining equivalent data accuracy. 25 In an HTS setting using a probe that possesses complex, multiexponential decays in both the free and the bound states, it is impractical to accurately fit such curves. However, in our experience, fitting the data to a single exponential decay equation is sufficient for both the screening and characterization of binding interactions such as those presented here.
Screen of 257 kinases for binding to AF647-staurosporine
One hundred seventy serine/threonine kinases and 87 tyrosine kinases were incubated at 10 µg/mL with 1 nM AF647staurosporine in the presence or absence of 1 µM staurosporine, and the fluorescence lifetime of the probe was measured (Tables 1 and 2). A total of 123 kinases (67 serine/threonine and 56 tyrosine kinases) showed a competable binding to the kinase that resulted in a greater than 100-ps change in fluorophore lifetime. This represents 39% of the serine/threonine kinases tested and 64% of the tyrosine kinases tested. In addition, 49 serine/threonine and 22 tyrosine kinases showed a competable change in lifetime between 25 and 100 ps. There were 21 serine/threonine and 7 tyrosine kinases for which a greater than 100-ps change in probe lifetime was observed in the presence of kinase but that was not competable by 1 µM staurosporine, presumably because of nonspecific interactions between the probe and the protein. Because the kinase screen was performed at a single concentration of kinase, the observed change in fluorescence lifetime of the probe between the free and bound states does not strictly define the maximum change in lifetime that could be observed for a particular kinase, as kinases with lower affinity for the probe may not bind all of the probe present under these conditions.
Titrations of representative Ser/Thr and Tyr kinases against AF647-staurosporine
Following the screen of 257 kinases, we measured affinity of the probe for 4 representative serine/threonine and 4 tyrosine kinases by performing a dilution of kinase against a 1 nM probe ( Fig. 2) . Of the serine/threonine kinases tested, the greatest change in probe lifetime was observed when bound to MARK2 and MARK4, with a change of 770 and 650 ps, respectively. PKC theta (PRKCQ) showed a change of 490 ps, and GSK3α (GSK3A) showed the smallest change upon binding, 330 ps. Of the tyrosine kinases tested (Syk, PDGFR-β [PDGFRB, catalytic domain], JAK3, and KDR [catalytic domain]), all showed lifetime changes ranging from 490 ps (Syk) to 550 ps (KDR).
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where σ + and σare the standard deviation of the positive and negative control wells, respectively, and µ + and µare the average values of those wells, respectively. In general, a Z′ value of > 0.5 is taken to be an indicator of an assay that is suitable for HTS. To empirically determine the change in lifetime required for a suitable HTS assay using AF647-staurosporine, we incubated MARK2 with a 1 nM probe at different kinase concentrations that caused a change in probe lifetime ranging from 113 to 476 ps. Single measurements were taken for 24 separate wells at each concentration of kinase (or no kinase for the negative control wells), and Z′ values were determined for the various probe lifetimes measured (Fig. 3) . This experiment established that a change in probe lifetime of 220 ps was sufficient to achieve a Z′ of >0.5 (σ + = 15 ps, σ -= 15 ps) and illustrates that extremely small changes in fluorescence lifetime can be determined with a degree of precision suitable for a robust high-throughput assay.
Displacement of AF647-staurosporine with small-molecule kinase inhibitors
To demonstrate the utility of the lifetime-based binding assay to characterize small-molecule kinase inhibitors, we performed titrations of 6 known kinase inhibitors on the same set of 8 kinases and determined IC 50 values ( Table 3) . The inhibitors used were selected to represent a broad range of potencies for the selected kinases. As expected, staurosporine displaced the AF647-staurosporine with low nanomolar IC 50 values for each of the kinases tested, whereas the other inhibitors demonstrated a broader spectrum of potencies. Although there is incomplete data in the literature regarding this specific collection of kinases and inhibitors, the rank-order data are consistent with published results. For example, tyrphostin AG1478 is reported to be a selective tyrosine kinase inhibitor that has high potency for the epidermal growth factor receptor protein 27 and does not compete the AF647-staurosporine from any of the tested serine/threonine kinases. SB-202190 has been reported as a potent and selective inhibitor of p38 MAP kinases 28, 29 and demonstrates poor binding (IC 50 values greater than 6.5 µM) to all kinases that we examined. Finally, Go6983 and Ro318220, both known inhibitors of the PKC family kinases 30, 31 displaced the AF647-staurosporine from PKC theta with low nanomolar IC 50 values.
Comparison of probe displacement and activity assay results
To further examine the ability of the binding assay to identify and characterize small-molecule inhibitors of kinase activity, we compared the AF647-staurosporine displacement data with inhibition data from 2 separate kinase activity assay formats using KDR and PKC theta, which were chosen as representative tyrosine and serine/threonine kinases, respectively ( Fig. 4; Table 4 ). For the tyrosine kinase KDR, rank-order potencies were identical between both activity assay formats and comparable to the binding assay in which a single set of compounds (Go6983 and Ro318220) showed reversed potencies. However, this pair of compounds showed similar potencies to one another in all formats. Three of the 6 inhibitors tested inhibited or bound to the serine/threonine kinase PKC One nM of AF647-staurosporine was incubated with 10 µg/mL of the indicated kinase in the presence or absence of 1 µM staurosporine in buffer consisting of 20 mM Tris, pH 7.5, and 0.01% NP-40. Kinases that showed between 100-and 200-ps change between bound and competed tracer are shown in italic, and kinases that showed greater than a 200 ps change are shown in bold. Kinases are identified according to the Hugo Gene Nomenclature Committee. theta, and although the rank-order potencies were again similar between all formats, these compounds exhibited IC 50 values in the binding assay that were 8-to 28-fold higher than seen in the activity assays. In the case of the PKC theta binding assay, 71 nM of kinase was required to elicit an 80% response in the change in probe lifetime, and the competition assays were performed at this concentration of kinase. This sets a lower theoretical minimum of approximately 35 nM in terms of an IC 50 value that could be determined in this configuration and therefore limits the ability of the assay, as configured, to resolve tight-binding compounds from one another. In contrast, the activity assays were performed with lower concentrations of kinase and can therefore resolve IC 50 values for more potent compounds. These differences may also reflect the intrinsic differences between the assay formats, and they suggest that for some kinases, the IC 50 data between binding and activity assay formats may not be comparable, as has been noted previously. 32 For both of the activity assays, the concentration of ATP was at the concentration that caused a half-maximal change in assay response in an ATP titration experiment, although this is not a true K m concentration of ATP, as no attempts were made to perform the assays under conditions of saturating peptide substrate. In addition, although it is straightforward to convert IC 50 values from the FRET-based activity to K i values if one knows the true ATP K m , it is more difficult to accurately do so for the TR-FRET-based assay, as the assay response is not strictly linear with respect to product formation but rather is dependant on the binding of a phosphorylated peptide to an antibody. In addition, the change in intensity of the probe between its free and bound state adds additional complexity to the analysis of a true K d value in the lifetimebased assay. 18 Despite these caveats, our results demonstrate that under the correct conditions, the fluorescence lifetime-based assay is able to accurately identify and characterize small-molecule kinase inhibitors in a simplified assay format.
Further differences in results between activity assays and binding assays may arise from the fact that the binding assays are not performed in the presence of peptide substrate, and if the binding of substrate to the kinase affects the affinity of the inhibitor for the kinase, such effects will not be noticed. An additional source of . 3 . Z′ determination of MARK2 assay at varying protein concentrations. Twenty-four replicates of varying concentrations of MARK2 were incubated with 1 nM AF647-staurosporine to generate a range of probe lifetimes, and Z′ was determined between free and bound probe for these wells. potential differences is that the binding assay is sensitive to probe and inhibitor binding to both active and nonactivated forms of the kinase, whereas in the activity assay, only inhibition of the active kinase is being measured. Although these factors complicate a direct comparison of results between formats, the comparison does highlight an advantage of the binding format in that it potentially facilitates the identification of inhibitors that bind to the nonactivated form of the kinase, without performing more complicated coupled assays.
Titrations of active and nonactivated kinases against AF647-staurosporine
To explore potential differences in probe binding between active and nonactivated forms of kinases, we performed binding assays with active and nonactivated forms of RPS6KA3 (RSK2) and MAPK12 (p38γ). The nonactivated forms of these kinases were originally purified in the nonactivated form and then activated in vitro by the relevant upstream kinases (PDK1 and MAPK for RPS6KA3 and MAP2K6 for MAPK12). In each example, probe binding to the active and nonactivated pairs of kinases demonstrated different characteristics (Fig. 5) .
In the case of MAPK12, we observed a significant difference between the binding affinities for the AF647-staurosporine probe (EC 50 of 16 nM for nonactivated MAPK12 v. 134 nM for the active form) but a similar change in probe lifetime between free and bound states for both forms of the kinase. For RPS6KA3, the binding affinities were similar for the nonactivated and active forms of kinase (EC 50 of 24 nM and 11 nM, respectively). However, there was a significant difference in the maximal lifetime shift of the probe upon binding (746 ps for nonactivated RPS6KA3 relative to 492 ps for the active form), reflecting a difference in the environment of the fluorophore when bound to the active or nonactivated form of the kinase. These data highlight differences that might be observed between binding and activity assays and suggest that care must be taken when interpreting the results of binding assays and correlating those results to more traditional kinase activity assays.
CONCLUSIONS
To date, the factors that appear to be limiting the application of fluorescence lifetime as a routine technology for HTS are lack of instrumentation capable of performing fluorescence lifetime measurements coupled with a lack of available assays. Although Six known kinase inhibitors were tested in 10-or 13-point dose-response curves at the EC 80 concentration of the kinase and 1 nM AF647-staurosporine. a. Partial displacement was observed. The data represent the results of a single experiment performed with triplicate wells for each concentration of inhibitor tested. several fluorescence lifetime-based model systems for monitoring biotin-streptavidin interactions using fluorophores with lifetimes in the nanosecond range have been described, 20, 21 it is unlikely that those results or the results presented in this or our previous study 18 can be generalized with respect to the applicability of a given fluorophore for use in a fluorescence lifetime-based assay. We have previously presented a model 18 (based on earlier work by others 33, 34 ) in which interactions between a fluorophore and a covalently tethered lipophilic ligand provides a nonradiative de-excitation pathway for the fluorophore. These interactions result in a decrease in fluorescence lifetime relative to when the ligand is bound to a receptor and no longer available to provide such a pathway. However, in our experience, the suitability of such a probe for a given application must be empirically determined. For example, we have developed dozens of fluorescence polarization-based assays for a range of target proteins using similarly constructed tracers, and only a small percentage of such tracers show a robust change in fluorescence lifetime upon binding to their receptors. Despite these issues, fluorescence lifetime is a useful technology to have at one's disposal when developing fluorescence-based competitive binding assays. When such assays are configured in a TR-FRET or other proximity-based format, the interacting components must be individually labeled, complicating the assay development process. Competitive binding assays can be developed in a fluorescence polarization format using a single labeled molecule, but short-lifetime fluorophores such as the one used here typically do not perform well in fluorescence polarization assays because the time between excitation and emission is short (relative to the tumbling rate of the fluorophore) whether the probe is free in solution or bound to the receptor, resulting in a small assay window. 35 Thus, direct measurement of fluorescence lifetime extends the range of fluorophores that can be used in homogenous competitive binding assays. Fluorescence lifetime can also be modulated via resonance energy transfer to an acceptor moiety, 36 but the engineering of such a moiety into a lifetime-based assay system remains complicated. However, FRET-based modulation of fluorophore lifetime has been successfully applied to microscopy-based lifetime measurements, typically using fluorescent protein fusions. 37 The fluorescence lifetime-based binding assay that we have developed shows the potential to be applied toward approximately one-third of the kinases that we initially screened. The assay is configured similar to that of a fluorescence polarization assay, in which a fluorescent probe (tracer) is incubated with a concentration of receptor (kinase, in our example), such that approximately 50% to 80% of the tracer is bound to the receptor in the absence of a competing ligand or inhibitor. The tracer is displaced from the receptor in the presence of an inhibitor that is capable of binding to the active site, causing a measurable change in the fluorescent properties of the tracer. For such an assay to be practical, it is important that the K d of the tracerreceptor interaction is low relative to the K i value for the inhibitor-receptor, because the lower limit of a K i value that can be determined in such an experiment is limited to approximately one-half the tracer-receptor K d . 38 In addition, lower K d values of the tracer-receptor complex mean that less receptor is required in the assay, which is important when the receptor is expensive or otherwise difficult to produce.
We developed our assay using a fluorescent conjugate of staurosporine, a broad-spectrum kinase inhibitor. Previous work by others had suggested that the 4′ nitrogen of staurosporine could be chemically modified without affecting the ability of staurosporine to bind tightly to its target kinases. To extend on the utility of our method, one would need to expand on the diversity of the ligands from which the tracer is derived by synthesizing additional tracers based on inhibitors that bind tightly to the kinases that do not tightly bind staurosporine. Kinase inhibitors that have been chemically modified yet retain affinity for their target(s) have been described, 12, 15, 16 but it would remain at least in part an empirical process to develop fluorescence lifetimebased assays based on such probes. Alternatively, fluorescent probes in which the fluorophore does not undergo a substantial change in fluorescence lifetime may be used to develop fluorescence polarization-based assays, 16 although the sometimes empirical nature of fluorescence polarization-based assay development should not be underestimated.
Although fluorescence lifetime measurements have been proposed to be resistant to interference from autofluorescent compounds, 39 this has not been our experience for compounds that absorb strongly within the excitation or emission spectrum of the probe fluorophore or autofluorescent compounds that possess lifetimes on the order of the probe being measured. 18 Although the interfering signals can be resolved from the probe signal under certain controlled conditions, 21 it has not been demonstrated that under conditions typical to HTS, using short read times per well, that such deconvolution is practical. From a practical standpoint, the use of red-shifted fluorophores such as Alexa Fluor ® 647 is a valid means of avoiding optical interference, as fewer compounds in typical compound libraries absorb or fluoresce at longer wavelengths. 35, 40 As an alternative strategy, time-resolved (gated) lifetime measurements using a fluorophore that possesses a lifetime on the order of several hundred nanoseconds has been described. 41 In such an assay, a delay of greater than 100 ns may be implemented before the fluorophore lifetime is calculated from the emission data, and in this manner, interference from autofluorescent compounds may be avoided.
We have developed a simple, fluorescence lifetime-based format for identifying and characterizing inhibitors of kinases by monitoring the displacement of a broadly applicable probe, AF647-staurosporine, from the ATP-binding site of a kinase. The format provides a simplified method to screen for inhibitors of kinases where traditional activity assays may not be practical, such as when a suitable substrate is not available or when inhibitors that bind to nonactivated kinases are desired. The method described could potentially be extended by conjugating the fluorophore to different inhibitors that bind to other subsets of kinases. Finally, the simplicity of the assay allows for compound screening of many kinases and would be suitable to use as a tool for HTS or for profiling compound specificity.
